Navigation Links
Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019
Date:5/15/2012

Preclinical Pipeline 545.4 Neuroendocrine Carcinoma Therapeutics- Clinical Pipeline by Mechanism of Action 555.5 Technology Trends Analytic Framework 555.6 Neuroendocrine Carcinoma Therapeutics - Key Late Stage Pipeline Drugs in Clinical Development 585.7 Molecule Profile for Key Late Stage Pipeline Drugs under Clinical Development 585.7.1 Avastin (bevacizumab) 585.7.2 Lutathera ([177Lutetium]-DOTA0-Tyr3-Octreotate) 595.7.3 Paseriotide (SOM 230) 605.7.4 Somatuline Autogel (lanreotide acetate) 615.8 Key Takeaway 616 Neuroendocrine Carcinoma Therapeutics - Clinical Trials Mapping 626.1 Clinical Trials by Region/Country (The US, EU5 and Japan) 626.2 Clinical Trials by Phase 636.3 Clinical Trials by Trial Status 646.4 Prominent Sponsors 656.5 Top Companies Participating in Neuroendocrine Carcinoma Therapeutics Clinical Trials 677 Neuroendocrine Carcinoma Therapeutics- Strategic Assessment 687.1 Future Market Competition Scenario 688 Neuroendocrine Carcinoma Therapeutics - Future Players 708.1 Introduction 708.2 Company Profiles for the Promising Drugs 708.2.1 Advanced Accelerator Applications S.A 708.2.2 Novartis AG 718.2.3 F. Hoffmann-La Roche 738.2.4 Ipsen SA 748.3 Other Companies in the Neuroendocrine Carcinoma Therapeutics Market 769 Neuroendocrine Carcinoma Therapeutics- Licensing and Partnership Deals 7710 Neuroendocrine Carcinoma Therapeutics - Appendix 7910.1 Market Definitions 7910.2 Abbreviations 7910.3 Methodology 8010.3.1 Coverage 8110.3.2 Secondary Research 8110.3.3 Forecasting 8110.3.4 Primary Research 8310.3.5 Expert Panel Validation 8410.4 Contact Us 8410.5 Disclaimer 8410.6 Bibliography 84

List of Tables

Table 1: GEP-NETs WHO Classification 7Table 2:GEP-NETs Classification 8Table 3: Historical Prevalence for Neuroendocrine Carcinoma* for Seven Major Markets 9Table 4: Forecast Prevalence for Neuroendocrine Carcinoma* for Seven Major Markets 10Table 5: Symptoms of Pancreatic NETs/Islet Cell Tumors 12Table 6:Diagnosis Techniques by S
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE
2. Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors
3. Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood
4. Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
5. SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for Adjuvant Treatment of Renal Cell Carcinoma
6. Targeted Gold Nanoparticles and Noninvasive Radio Fields Attacking One of the Deadliest and Least Curable Types of Cancer: Pancreatic Carcinoma
7. Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
8. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
9. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
10. Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRC-LAMP-Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy
11. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... (PRWEB) May 21, 2015 Specialty ... audit and been admitted to BPA Worldwide as ... Worldwide will track audience data for Specialty Pharmacy ... , “By becoming a member of BPA ... to providing our clients with the most reliable, ...
(Date:5/21/2015)... Calif. , May 21, 2015  The ... Orrin Hatch (R-UT) and Amy Klobuchar ... Extensions Now Accelerating Cures & Treatments, or OPEN ... rare disease patient advocacy organizations, this bipartisan legislation ... and affordable medicines to rare disease patients by ...
(Date:5/21/2015)...  CytRx Corporation (NASDAQ: CYTR ), a ... today announced positive updated results from its ongoing ... treatment of unresectable glioblastoma multiforme (GBM), a deadly ... is designed to investigate the preliminary efficacy and ... progressed following prior treatment with surgery, radiation and ...
(Date:5/21/2015)... Veolia’s environmental monitoring technology division, Endetec, ... agreement with VWR to distribute TECTA™ B16, an ... 160 years of experience, VWR, a leading global ... production facilities, has cultivated a value proposition delivering ... enable science. Endetec’s TECTA™ B16, combines proven ...
Breaking Biology Technology:Specialty Pharmacy Times Joins BPA Worldwide 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2
... CHARENTON-LE-PONT, France, August 28 , - Hubert ... The Board of Directors of Essilor International today ... alongside Xavier Fontanet,Chief Executive Officer, and Philippe Alfroid, ... Centrale in Lille and holder of an MBA ...
... N.J., Aug. 27 BD (Becton,Dickinson and Company) (NYSE: ... that it would present at the following investor healthcare,conferences:, ... 4, 2008 1:30 p.m. EDT, Morgan Stanley ... 8:00 a.m. EDT, A live webcast of BD,s ...
... of,Directors, meeting today under the chairmanship of Albert Saporta, approved,STALLERGENES, half year consolidated financial statements:, (EUR millions) ... ... % ... ...
Cached Biology Technology:Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit 2Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit 3
(Date:4/14/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... York Design Awards under the category  ,Product Design – ... Awards are part of a global multi-disciplinary awards program. ... the marketplace, industry and judging panel. Winners will be ...
(Date:4/9/2015)... SAN JOSE, Calif. , April 9, 2015 /PRNewswire/ ... of human interface solutions, announced today that it will ... 2015 on Thursday, April 23, 2015, after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
(Date:4/2/2015)... , April 2, 2015 At its ... Salt Lake City , the American College of ... five new directors to its Board.  Members of the ... ACMG and for forming and advancing its policies and ... genetics profession. "It,s an eventful time in ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
... 28, 2008--As atmospheric CO2 levels rise, methods to mitigate ... in the July-August 2008 issue of Soil Science ... of soils as a C sink in different regions ... Rural Development (Canada), the National Institute of Agricultural Technology, ...
... researchers have developed a new technology that promises ... readily available non-food crops, such as Bermudagrass, switchgrass, ... ethanol from renewable biomass sources such as grasses ... large quantities," said Joy Peterson, professor of microbiology ...
... Strange things are happening in the lowland tropical forests ... fly is affecting the social behavior of a nocturnal ... which become workers. The finding by researchers from ... Institute is the first documented example of a parasite ...
Cached Biology News:Soil's carbon storage capacity investigated 2Soil's carbon storage capacity investigated 3New UGA biomass technology dramatically increases ethanol yield from grasses and yard waste 2New UGA biomass technology dramatically increases ethanol yield from grasses and yard waste 3A bee's future as queen or worker may rest with parasitic fly 2
... of Flight Mass Analyzer for superior sensitivity, mass accuracy, and resolving ... m/z, * Precursor ion selection range: 150 - 4000 m/z, * ... with internal reference, * Dynamic range: 4 orders of magnitude ... ...
Four siRNAs targeting your gene of interest, providing gene silencing with 100% satisfaction guaranteed High knockdown potency , High specificity for minimal off-target effects , Flexible siR...
Mouse polyclonal antibody to BTAF1 - BTAF1 RNA polymerase II, B-TFIID transcription factor-associated, 170kDa (Mot1 homolog, S. cerevisiae)...
... combines Harvard Apparatuss best pump mechanism, a well ... of configuration options. A lookup table in the ... all the major manufacturers. A bright, two line ... from across the lab. All models have RS-232 ...
Biology Products: